An increased CD8/FOXP3+ TIL ratio in pretreatment biopsies significantly correlated with pCR in TNBC and HER2-positive breast cancer, following FEC100 and paclitaxel + trastuzumab respectively. The gene discussed is FOXP3; the disease is breast carcinoma.